Developer docs
API playgroundTry for free, no card

Search company profiles

Esco Aster

Full company profile

uuid000g2z9

Namestring
Esco Aster
Legal namestring
Esco Aster Pte Ltd
Websiteurl
escoaster.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Esco Aster Pte Ltd is a Singapore-based Contract Research, Development and Manufacturing Organization (CRDMO) that delivers end-to-end biopharmaceutical services spanning consultancy, drug discovery, process and CMC development, cGMP manufacturing, GLP toxicology, clinical trial material, aseptic fill-and-finish, stability testing, clinical development, and strategic capital fundraising support. The company serves pharmaceutical and biotechnology companies (its primary segment), animal health firms, cosmetics/cosmeceuticals brands, food and cellular agriculture companies, and healthcare and medical centers across ASEAN, East Asia, ANZ, South Asia, the UK, and the US.

The company's core differentiator is its proprietary Adherent Tide Motion® packed-bed adherent cell bioreactor platform, which enables linearly scalable manufacturing from 0.1L to 5,000L packed-bed volume (bioequivalent to 50,000L suspension). This platform is extended through adjacent technologies including 3D Tide Motion® (mimicking lung-like microenvironments for physiologically relevant cell behavior), Astericle™ (extracellular vesicle/exosome manufacturing), MiniTide® (3D dynamic culture for drug discovery and toxicology), Esco AsterMavors® (cellular agriculture and complementary proteins), continuous fermentation (liquid and solid-state), continuous flow chemistry for API synthesis, and perfusion-enabled Tide Motion® with integrated SMB/RMB chromatography. Production facilities in Singapore, Taiwan, Japan, China, South Korea, the UK, and the US operate under cGMP, GLP, AAALAC, ISO, and SFA certifications, with the SFA certification marking the world's first for a cultivated cell-based nutrition and meat facility.

Esco Aster operates a horizontally segmented, multi-modality business model combining fee-for-service project work, FTE-based collaborations, funded research, shared-risk co-development partnerships with IP licensing and royalties, inward licensing arrangements, and consultancy/strategic capital services. The company monetizes across modalities including viral and DNA vaccines, viral vectors (lentivirus, retrovirus, AAV), cell therapies (MSC, iPSC, CAR-T, including canine CAR-T), plasmid DNA, lipid nanoparticles, exosomes/extracellular vesicles, therapeutic peptides, monoclonal antibodies, APIs, cosmeceuticals (AsterCura™), and cultivated meat/seafood. It operates as an affiliate of Esco Lifesciences Group, which was founded in 1978 in Singapore and collectively employs approximately 1,700 staff across 42 locations in 25 countries; Esco Aster itself was established in 2015 as an intrapreneurial venture, spun out as a subsidiary in 2018, and completed its formal spin-off as an independent affiliate on 8 August 2022.

Short descriptiontext

Esco Aster is a Singapore-based CRDMO offering end-to-end biopharmaceutical development and manufacturing services — from drug discovery and cGMP production to clinical and commercial scale — built on its proprietary Tide Motion® packed-bed bioreactor platform. It serves pharma, biotech, animal health, cosmeceuticals, and cellular agriculture clients across Asia, the UK, and the US.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical contract manufacturing, cell and gene therapy CDMO, viral vector production services, adherent bioreactor platforms, vaccine and exosome manufacturing
Industry7 codes
PRIMARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAGAE
Process Development & Tech Transfer (Upstream/Downstream/MSAT)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAJAG
Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAMANAI
Veterinary Regenerative Medicine Manufacturing (GMP/CDMO, Cell Processing)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Food Manufacturing311
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Contract Manufacturing (CRDMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Contract Manufacturing Services (CRDMO)
TypeProfessional Services
Description

Fee-for-service contract research, development, and manufacturing services spanning from early development through GLP tox, clinical trial material, and commercial production. Services include drug discovery, process development, cGMP manufacturing, testing, clinical development, and regulatory support.

escoaster.com
2Co-development Partnerships
TypeLicensing Royalties
Description

Shared risk partnered co-development projects involving exclusive inward licensing of Background IP and ability to outward license/sub-license co-developed Foreground IP with subsequent royalties on sales.

escoaster.com
3Strategic Capital Fundraising Services
TypeProfessional Services
Description

Fundraising as a service to align capital, capability, and execution for founders, startups, investors, and government research bodies.

escoaster.com
4Consultancy Services
TypeProfessional Services
Description

Specialized biomanufacturing consultancy helping startups and biotech companies achieve critical fundraising and investment milestones.

escoaster.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Astericle™
Description

Extracellular vesicle (EV) platform brand for partnering with cell and gene therapy businesses.

escoaster.com
+2 more records
Core offering1 text field

Esco Aster is a vertically integrated Contract Research, Development and Manufacturing Organization (CRDMO) providing end-to-end services from early-stage consultancy and drug discovery through process development, cGMP manufacturing, testing, and clinical development, covering gene therapy, cell therapy, viral vector and plasmid DNA production, human and animal vaccines, extracellular vesicles (Astericle), therapeutic peptides, APIs, cosmeceuticals (AsterCura), and cellular agriculture (Esco AsterMavors). Its offerings are built around the proprietary Adherent Tide Motion® packed-bed bioreactor platform, which enables linearly scalable manufacturing from 0.1L to 5,000L packed-bed volume for adherent cell-based bioprocesses.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • High viral titers in range of 8 log10 achieved with Tide Motion® bioreactors for Vero-cell based vaccine production
+2 more records
Product overview1 text field

Esco Aster is a vertically integrated Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end bioinnovation solutions from idea to exit. The company operates a platform-plus-services architecture built around its proprietary Adherent Tide Motion bioreactor technology. Core products span biopharmaceutical manufacturing including Gene Therapy, Cell Therapy, Viral Vector Production, Plasmid DNA Manufacturing, and Human Vaccines services. The company also offers Extracellular Vesicles (Astericle) and Exosome services for drug delivery, alongside Human Vaccines production. Supporting services include GLP Toxicology, Clinical Development, Aseptic Fill & Finish, Stability Testing, and Container Closure Integrity Testing. The platform includes continuous fermentation and flow chemistry capabilities, as well as specialized offerings in Cellular Agriculture (Esco AsterMavors), Cosmetics/Cosmeceuticals (AsterCura), and Therapeutic Peptides. Business support services include Consultancy, COGS & Techno-Economic Analysis, and Strategic Capital fundraising support.

Product and service1 record
1Gene Therapy CDMO Services
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-06
Description

Esco Aster signed a clinical cGMP manufacturing contract with Shine-On Biomedical to support their HLA-G-targeted exosome drug delivery platform. Shine-On's lead product SOB100 received US FDA IND clearance in Q1 2025 and is undergoing Phase I clinical study, positioning it as potentially first-in-class HLA-G-targeted exosome platform. Esco Aster provides cGMP manufacturing and technical services for exosome loading feasibility studies, leveraging its 3D Tide Motion bioreactor technology for cost-efficient GMP manufacturing for Asia-Pacific innovators.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

China-headquartered CRDMO offering discovery, process development, and biologics/small-molecule manufacturing services. Comparable to Esco Aster as a vertically integrated CRDMO serving global biotech and pharma customers across modalities.

TypeDirect peer
Description

CDMO specializing in biologics, viral vaccines, and gene therapy manufacturing. Directly comparable to Esco Aster across vaccine, gene therapy, and mammalian cell culture CDMO services, with broader global capacity.

TypeDirect peer
Description

Specialty CDMO with strong continuous flow chemistry, small-molecule API, and biologics capabilities. Comparable to Esco Aster in continuous flow chemistry, peptide manufacturing, and integrated drug substance/drug product services.

TypeBroad incumbent
Description

Diversified life-sciences giant whose Patheon/CDMO services business competes directly with Esco Aster in biologics, viral vectors, and clinical/commercial drug product manufacturing. Co-mentioned alongside Esco Aster as a leading player in the Singapore exosomes market.

TypeDirect peer
Description

Mid-to-large biologics CDMO offering mammalian and microbial production, gene therapy, and cell therapy services. Closely comparable to Esco Aster as a multi-modality biologics CDMO.

TypeDirect peer
Description

Europe-based biologics CDMO offering mammalian cell line development, GMP manufacturing, and aseptic fill-finish. Comparable to Esco Aster as a mid-sized, multi-modality biologics CDMO targeting biotech customers.

TypeBroad incumbent
Description

World's largest contract biologics manufacturer offering mammalian cell culture, viral vector, and cell therapy CDMO services. Directly comparable to Esco Aster across biologics and cell/gene therapy manufacturing, though Lonza operates at materially larger scale with broader modality coverage.

TypeBroad incumbent
Description

Large-scale Korean CDMO with mega-plant biologics manufacturing capacity. Comparable to Esco Aster in serving biologics manufacturing demand from Asia-Pacific, though with a different scale and modality mix focused on mammalian bioreactor systems.

TypeDirect peer
Description

Global CDMO with biologics, cell therapy, and aseptic fill-finish capabilities. Comparable to Esco Aster across end-to-end biopharmaceutical development, manufacturing, and fill-finish services.

TypeDirect peer
Description

Leading Asia-based biologics CDMO with end-to-end discovery, development, and manufacturing services. Highly comparable to Esco Aster as a regional CRDMO competitor serving global biotech customers with cGMP biologics capacity.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks2 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Esco Aster

Biopharmaceutical Contract Manufacturing (CRDMO)escoaster.com

Esco Aster is a Singapore-based CRDMO offering end-to-end biopharmaceutical development and manufacturing services — from drug discovery and cGMP production to clinical and commercial scale — built on its proprietary Tide Motion® packed-bed bioreactor platform. It serves pharma, biotech, animal health, cosmeceuticals, and cellular agriculture clients across Asia, the UK, and the US.

What Esco Aster does

Esco Aster Pte Ltd is a Singapore-based Contract Research, Development and Manufacturing Organization (CRDMO) that delivers end-to-end biopharmaceutical services spanning consultancy, drug discovery, process and CMC development, cGMP manufacturing, GLP toxicology, clinical trial material, aseptic fill-and-finish, stability testing, clinical development, and strategic capital fundraising support. The company serves pharmaceutical and biotechnology companies (its primary segment), animal health firms, cosmetics/cosmeceuticals brands, food and cellular agriculture companies, and healthcare and medical centers across ASEAN, East Asia, ANZ, South Asia, the UK, and the US.

The company's core differentiator is its proprietary Adherent Tide Motion® packed-bed adherent cell bioreactor platform, which enables linearly scalable manufacturing from 0.1L to 5,000L packed-bed volume (bioequivalent to 50,000L suspension). This platform is extended through adjacent technologies including 3D Tide Motion® (mimicking lung-like microenvironments for physiologically relevant cell behavior), Astericle™ (extracellular vesicle/exosome manufacturing), MiniTide® (3D dynamic culture for drug discovery and toxicology), Esco AsterMavors® (cellular agriculture and complementary proteins), continuous fermentation (liquid and solid-state), continuous flow chemistry for API synthesis, and perfusion-enabled Tide Motion® with integrated SMB/RMB chromatography. Production facilities in Singapore, Taiwan, Japan, China, South Korea, the UK, and the US operate under cGMP, GLP, AAALAC, ISO, and SFA certifications, with the SFA certification marking the world's first for a cultivated cell-based nutrition and meat facility.

Esco Aster operates a horizontally segmented, multi-modality business model combining fee-for-service project work, FTE-based collaborations, funded research, shared-risk co-development partnerships with IP licensing and royalties, inward licensing arrangements, and consultancy/strategic capital services. The company monetizes across modalities including viral and DNA vaccines, viral vectors (lentivirus, retrovirus, AAV), cell therapies (MSC, iPSC, CAR-T, including canine CAR-T), plasmid DNA, lipid nanoparticles, exosomes/extracellular vesicles, therapeutic peptides, monoclonal antibodies, APIs, cosmeceuticals (AsterCura™), and cultivated meat/seafood. It operates as an affiliate of Esco Lifesciences Group, which was founded in 1978 in Singapore and collectively employs approximately 1,700 staff across 42 locations in 25 countries; Esco Aster itself was established in 2015 as an intrapreneurial venture, spun out as a subsidiary in 2018, and completed its formal spin-off as an independent affiliate on 8 August 2022.

Esco Aster firmographics

Firmographics
Name
Esco Aster
Legal name
Esco Aster Pte Ltd
Website
https://escoaster.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Esco Aster is a Singapore-based CRDMO offering end-to-end biopharmaceutical development and manufacturing services — from drug discovery and cGMP production to clinical and commercial scale — built on its proprietary Tide Motion® packed-bed bioreactor platform. It serves pharma, biotech, animal health, cosmeceuticals, and cellular agriculture clients across Asia, the UK, and the US.
Ownership category
akta.pro rank

Esco Aster industry classification

Industry
Product category
Biopharmaceutical Contract Manufacturing (CRDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Food Manufacturing (311)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAGAE
Process Development & Tech Transfer (Upstream/Downstream/MSAT)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAJAG
Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAMANAI
Veterinary Regenerative Medicine Manufacturing (GMP/CDMO, Cell Processing)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Biopharmaceutical contract manufacturing
  • Cell and gene therapy CDMO
  • Viral vector production services
  • Adherent bioreactor platforms
  • Vaccine and exosome manufacturing

Where Esco Aster is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices8 records

Markets served

Esco Aster business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Manufacturing Services (CRDMO): Fee-for-service contract research, development, and manufacturing services spanning from early development through GLP tox, clinical trial material, and commercial production. Services include drug discovery, process development, cGMP manufacturing, testing, clinical development, and regulatory support.
  2. Co-development Partnerships: Shared risk partnered co-development projects involving exclusive inward licensing of Background IP and ability to outward license/sub-license co-developed Foreground IP with subsequent royalties on sales.
  3. Strategic Capital Fundraising Services: Fundraising as a service to align capital, capability, and execution for founders, startups, investors, and government research bodies.
  4. Consultancy Services: Specialized biomanufacturing consultancy helping startups and biotech companies achieve critical fundraising and investment milestones.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Esco Aster product offering

Product offering

Core offering

Esco Aster is a vertically integrated Contract Research, Development and Manufacturing Organization (CRDMO) providing end-to-end services from early-stage consultancy and drug discovery through process development, cGMP manufacturing, testing, and clinical development, covering gene therapy, cell therapy, viral vector and plasmid DNA production, human and animal vaccines, extracellular vesicles (Astericle), therapeutic peptides, APIs, cosmeceuticals (AsterCura), and cellular agriculture (Esco AsterMavors). Its offerings are built around the proprietary Adherent Tide Motion® packed-bed bioreactor platform, which enables linearly scalable manufacturing from 0.1L to 5,000L packed-bed volume for adherent cell-based bioprocesses.

Product overview

Esco Aster is a vertically integrated Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end bioinnovation solutions from idea to exit. The company operates a platform-plus-services architecture built around its proprietary Adherent Tide Motion bioreactor technology. Core products span biopharmaceutical manufacturing including Gene Therapy, Cell Therapy, Viral Vector Production, Plasmid DNA Manufacturing, and Human Vaccines services. The company also offers Extracellular Vesicles (Astericle) and Exosome services for drug delivery, alongside Human Vaccines production. Supporting services include GLP Toxicology, Clinical Development, Aseptic Fill & Finish, Stability Testing, and Container Closure Integrity Testing. The platform includes continuous fermentation and flow chemistry capabilities, as well as specialized offerings in Cellular Agriculture (Esco AsterMavors), Cosmetics/Cosmeceuticals (AsterCura), and Therapeutic Peptides. Business support services include Consultancy, COGS & Techno-Economic Analysis, and Strategic Capital fundraising support.

Differentiator

Problem solved

Functional benefit

Brands

  • Astericle™: Extracellular vesicle (EV) platform brand for partnering with cell and gene therapy businesses.
  • AsterCura™
  • Esco AsterMavors®

Products and services

  • Gene Therapy CDMO Services

Quantifiable outcome

  • High viral titers in range of 8 log10 achieved with Tide Motion® bioreactors for Vero-cell based vaccine production
  • +2 more outcomes

Companies that use Esco Aster

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles5 records

Esco Aster technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Esco Aster partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Shine-On BiomedicalcoreStrategic or Co-development Partner · 6 January 2026Esco Aster signed a clinical cGMP manufacturing contract with Shine-On Biomedical to support their HLA-G-targeted exosome drug delivery platform. Shine-On's lead product SOB100 received US FDA IND clearance in Q1 2025 and is undergoing Phase I clinical study, positioning it as potentially first-in-class HLA-G-targeted exosome platform. Esco Aster provides cGMP manufacturing and technical services for exosome loading feasibility studies, leveraging its 3D Tide Motion bioreactor technology for cost-efficient GMP manufacturing for Asia-Pacific innovators.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Esco Aster competitors and assessment

Company assessment

Direct peers

  • Pharmaron: China-headquartered CRDMO offering discovery, process development, and biologics/small-molecule manufacturing services. Comparable to Esco Aster as a vertically integrated CRDMO serving global biotech and pharma customers across modalities.
  • FUJIFILM Diosynth Biotechnologies: CDMO specializing in biologics, viral vaccines, and gene therapy manufacturing. Directly comparable to Esco Aster across vaccine, gene therapy, and mammalian cell culture CDMO services, with broader global capacity.
  • Hovione: Specialty CDMO with strong continuous flow chemistry, small-molecule API, and biologics capabilities. Comparable to Esco Aster in continuous flow chemistry, peptide manufacturing, and integrated drug substance/drug product services.
  • AGC Biologics: Mid-to-large biologics CDMO offering mammalian and microbial production, gene therapy, and cell therapy services. Closely comparable to Esco Aster as a multi-modality biologics CDMO.
  • Celonic Group: Europe-based biologics CDMO offering mammalian cell line development, GMP manufacturing, and aseptic fill-finish. Comparable to Esco Aster as a mid-sized, multi-modality biologics CDMO targeting biotech customers.
  • Catalent: Global CDMO with biologics, cell therapy, and aseptic fill-finish capabilities. Comparable to Esco Aster across end-to-end biopharmaceutical development, manufacturing, and fill-finish services.
  • WuXi Biologics: Leading Asia-based biologics CDMO with end-to-end discovery, development, and manufacturing services. Highly comparable to Esco Aster as a regional CRDMO competitor serving global biotech customers with cGMP biologics capacity.

Broad incumbents

  • Thermo Fisher Scientific (Patheon CDMO): Diversified life-sciences giant whose Patheon/CDMO services business competes directly with Esco Aster in biologics, viral vectors, and clinical/commercial drug product manufacturing. Co-mentioned alongside Esco Aster as a leading player in the Singapore exosomes market.
  • Lonza: World's largest contract biologics manufacturer offering mammalian cell culture, viral vector, and cell therapy CDMO services. Directly comparable to Esco Aster across biologics and cell/gene therapy manufacturing, though Lonza operates at materially larger scale with broader modality coverage.
  • Samsung Biologics: Large-scale Korean CDMO with mega-plant biologics manufacturing capacity. Comparable to Esco Aster in serving biologics manufacturing demand from Asia-Pacific, though with a different scale and modality mix focused on mammalian bioreactor systems.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks2 records

Key highlights6 records

Customer concentration

Esco Aster social profiles

Digital presence

Esco Aster compliance and trust

Trust signal

Compliance5 records

Esco Aster financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Esco Aster leadership team

Management profile

Number of profiles

Esco Aster subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Esco Aster funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Esco Aster M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Esco Aster

What does Esco Aster do?

Esco Aster is a vertically integrated Contract Research, Development and Manufacturing Organization (CRDMO) providing end-to-end services from early-stage consultancy and drug discovery through process development, cGMP manufacturing, testing, and clinical development, covering gene therapy, cell therapy, viral vector and plasmid DNA production, human and animal vaccines, extracellular vesicles (Astericle), therapeutic peptides, APIs, cosmeceuticals (AsterCura), and cellular agriculture (Esco AsterMavors). Its offerings are built around the proprietary Adherent Tide Motion® packed-bed bioreactor platform, which enables linearly scalable manufacturing from 0.1L to 5,000L packed-bed volume for adherent cell-based bioprocesses.

Is Esco Aster a public or private company?

Esco Aster is a private company. It is classified as family owned and is currently operating.

When was Esco Aster founded?

Esco Aster was founded in 2015. It employs 51 to 100 people.

Where is Esco Aster based?

Esco Aster is headquartered in Singapore, Singapore, in the Asia region.

How does Esco Aster make money?

Four revenue lines are on record. Contract Manufacturing Services (CRDMO) is the primary driver. The others are co-development Partnerships, strategic Capital Fundraising Services and consultancy Services.

Who are Esco Aster's main competitors?

Direct peers on record are Pharmaron, FUJIFILM Diosynth Biotechnologies, Hovione, AGC Biologics, Celonic Group, Catalent and WuXi Biologics. Broad incumbents are Thermo Fisher Scientific (Patheon CDMO), Lonza and Samsung Biologics.

Does Esco Aster have an API?

No public API is recorded for Esco Aster.

What industry is Esco Aster in?

Esco Aster's product category is Biopharmaceutical Contract Manufacturing (CRDMO). Its primary akta.pro industry code is HLAGAGAG, Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP), with a secondary code of HLAGAGAE, Process Development & Tech Transfer (Upstream/Downstream/MSAT). Its NAICS code is 325412 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comSingapore Exosomes Research:CAGR of 18.2% during the forecast periodQYResearch published a market research report projecting the Singapore exosomes market to reach USD 0.05 billion by 2032, growing at a compound annual growth rate of 18.2% during the forecast period 2026-2032. The report identifies Thermo Fisher Scientific, Qiagen, CellResearch, and Esco Aster as the leading players in Singapore's exosomes market, collectively accounting for approximately 54.0% of market revenue in 2025. Scientific research products represent the dominant product segment at 68.6%, while tumor-related applications hold the largest share by application at 44.9%.PR NewswireEsco Aster unterzeichnet klinischen cGMP-Herstellungsvertrag mit Shine-On Biomedical für eine neuartige, erstmals in ihrer Klasse verfügbare, HLA-G-gerichtete Exosomenplattform zur WirkstoffabgabeEsco Aster, a vertically integrated Contract Research, Development and Manufacturing Organization (CRDMO) based in Singapore, signed a clinical cGMP manufacturing contract with Shine-On Biomedical to support the latter's HLA-G-targeted exosome drug delivery program. Shine-On's lead product SOB100 received US FDA IND clearance in Q1 2025 and is currently undergoing a Phase I clinical study, positioning it as a potentially first-in-class HLA-G-targeted exosome platform. Esco Aster will also provide technical services for exosome loading feasibility studies and is evaluating single-use cGMP workflows at China Medical University Hospital.PR NewswireEsco Aster signe avec Shine-On Biomedical un contrat de fabrication clinique d'exosomes, conforme aux BPF en vigueur, pour une nouvelle plateforme HLA-G ciblant l'administration de médicaments exosomiEsco Aster, a Singapore-based contract research, development and manufacturing organization (CRDMO), has signed a GMP-compliant clinical manufacturing agreement with Shine-On Biomedical for the production of exosomes targeting the HLA-G drug delivery platform. Shine-On's proprietary product candidate SOB100 received FDA Investigational New Drug (IND) authorization in Q1 2025 and is currently undergoing Phase I clinical study, making it the first-in-class HLA-G targeted exosome platform in development. Esco Aster will also provide technical services for exosome loading feasibility studies and is leveraging its 3D Tide Motion bioréactor technology to support cost-efficient GMP manufacturing for Asia-Pacific innovators.PR NewswireEsco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery PlatformEsco Aster announced a contract to support Shine-On Biomedical's exosome drug delivery platform, including cGMP manufacturing and technical services, with the U.S. FDA IND approval of Shine-On's SOB100 product. The collaboration aims to develop first-in-class HLA-G targeted exosome therapies and support further preclinical and clinical studies.AETOSWireAleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO Aster PartnershipAleph Farms acquired a manufacturing facility in Modi'in, Israel, from VBL Therapeutics and signed an MOU with ESCO Aster to produce cultivated meat in Singapore. The agreements aim to increase production capabilities ahead of commercialization, with plans for additional strategic assets worldwide.Business Wire IndiaEsco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery PlatformEsco Aster has signed a contract to provide cGMP manufacturing support for Shine-On Biomedical's HLA-G targeted exosome drug delivery program. This collaboration followed Esco Aster's sponsorship of Shine-On in 2023, which supported the IND submission that was cleared by the U.S. FDA in Q1 2025. The partnership aims to leverage Esco Aster's bioreactor technology to lower costs and strengthen its position as a CRDMO in Singapore.BioinformantEsco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery PlatformEsco Aster has signed a contract to provide cGMP manufacturing services for Shine-On Biomedical's HLA-G targeted exosome drug delivery platform. This collaboration supports the development and ongoing Phase I study of Shine-On's proprietary product, SOB100, which previously received U.S. FDA IND clearance in Q1 2025. The partnership aims to leverage Esco Aster's bioreactor technology to lower costs and strengthen Singapore's bioeconomy.Business Wire BlogMosa Meat and Esco Aster Announce Partnership to Produce Cultivated Beef in SingaporeMosa Meat and Esco Aster signed an agreement to produce cultivated beef in Singapore, with the ceremony facilitated by the Dutch embassy. The partnership enables production on two continents, reducing shipping carbon footprint. Mosa Meat's 77,000 sq. foot facility is the world's largest cultivated meat campus.foodnavigator.comDutch food tech pioneer Meatable partners with ESCO Aster to bring cultivated pork to SingaporeMeatable partnered with ESCO Aster to bring cultivated pork products to Singapore, aiming to launch restaurant products by 2024 and supermarket sales by 2025. The first products will be dumplings and sausages, with regulatory approvals still pending. Meatable plans to expand globally once other countries grant regulatory approval.FortuneCan cultured meat replace real meat? Yes, if the tech world steps upSingapore became the first country to approve the sale of cultured chicken meat, with Eat Just producing the product in Esco Aster's bioreactors. The article argues governments must develop supportive policies to unlock the $150 billion syn-bio market, citing Singapore's 30% local food goal by 2030.